Purpose : To evaluate whether cystatin C in serum (sCyC) and urine (uCyC) can predict early acute kidney injury (AKI) in a mixed heterogeneous intensive care unit (ICU), and also whether these biomarkers can predict the need for renal replacement therapy (RRT). Methods: Multicenter prospective observational cohort study in patients =18 years old and with expected ICU stay =72 h. The RIFLE class for AKI was calculated daily, while sCyC and uCyC were determined on days 0, 1, and alternate days until ICU discharge. Test characteristics were calculated to assess the diagnostic performance of CyC. Results: One hundred fifty-one patients were studied, and three groups were defined: group 0 (N = 60), non-AKI; group 1 (N = 35), AKI after admission;...
BackgroundAcute kidney injury (AKI) is common after cardiac surgery and is associated with adverse p...
<p>Introduction <br /> Serum cystatin C measurements as an early biomarker of acute kidney injury (A...
Objective: We aimed to evaluate the effectiveness of renal biomarkers (NGAL, KIM-1, IL-18, and Cysta...
To evaluate whether cystatin C in serum (sCyC) and urine (uCyC) can predict early acute kidney injur...
Background: Acute kidney injury (AKI) is a common problem in critically ill patients and is independ...
Background/Aims: Acute Kidney Injury (AKI) is a serious clinical state associated with high morbidit...
Background: The early diagnosis of AKI in patients with sepsis would assist in more-effective care f...
PURPOSE: Acute kidney injury (AKI) is common in critically ill patients. Serum cystatin C has emer...
Background: The early diagnosis of AKI in patients with sepsis would assist in more-effective care f...
Introduction: Plasma Cystatin C (CysC) is as an early functional marker for acute kidney injury. Est...
Serum cystatin C increases earlier than creatinine during acute kidney injury. However, whether cyst...
BACKGROUND: Recent research has shown cystatin C to predict mortality and cardiovascular morbidity i...
Introduction: Plasma Cystatin C (pCysC) is one of the functional biomarker for AKI. This study evalu...
Background/Aims: There is a paucity of literature that investigates a biomarker associated with succ...
BACKGROUND AND OBJECTIVES: The diagnosis of acute kidney injury (AKI) is usually based on changes in...
BackgroundAcute kidney injury (AKI) is common after cardiac surgery and is associated with adverse p...
<p>Introduction <br /> Serum cystatin C measurements as an early biomarker of acute kidney injury (A...
Objective: We aimed to evaluate the effectiveness of renal biomarkers (NGAL, KIM-1, IL-18, and Cysta...
To evaluate whether cystatin C in serum (sCyC) and urine (uCyC) can predict early acute kidney injur...
Background: Acute kidney injury (AKI) is a common problem in critically ill patients and is independ...
Background/Aims: Acute Kidney Injury (AKI) is a serious clinical state associated with high morbidit...
Background: The early diagnosis of AKI in patients with sepsis would assist in more-effective care f...
PURPOSE: Acute kidney injury (AKI) is common in critically ill patients. Serum cystatin C has emer...
Background: The early diagnosis of AKI in patients with sepsis would assist in more-effective care f...
Introduction: Plasma Cystatin C (CysC) is as an early functional marker for acute kidney injury. Est...
Serum cystatin C increases earlier than creatinine during acute kidney injury. However, whether cyst...
BACKGROUND: Recent research has shown cystatin C to predict mortality and cardiovascular morbidity i...
Introduction: Plasma Cystatin C (pCysC) is one of the functional biomarker for AKI. This study evalu...
Background/Aims: There is a paucity of literature that investigates a biomarker associated with succ...
BACKGROUND AND OBJECTIVES: The diagnosis of acute kidney injury (AKI) is usually based on changes in...
BackgroundAcute kidney injury (AKI) is common after cardiac surgery and is associated with adverse p...
<p>Introduction <br /> Serum cystatin C measurements as an early biomarker of acute kidney injury (A...
Objective: We aimed to evaluate the effectiveness of renal biomarkers (NGAL, KIM-1, IL-18, and Cysta...